(NASDAQ: APGE) Apogee Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.43%.
Apogee Therapeutics's earnings in 2025 is -$253,674,000.On average, 17 Wall Street analysts forecast APGE's earnings for 2025 to be -$295,286,862, with the lowest APGE earnings forecast at -$296,072,544, and the highest APGE earnings forecast at -$291,249,136. On average, 17 Wall Street analysts forecast APGE's earnings for 2026 to be -$339,729,171, with the lowest APGE earnings forecast at -$410,426,944, and the highest APGE earnings forecast at -$278,985,655.
In 2027, APGE is forecast to generate -$401,832,259 in earnings, with the lowest earnings forecast at -$702,345,618 and the highest earnings forecast at -$285,940,654.